39
Participants
Start Date
December 21, 2015
Primary Completion Date
September 1, 2016
Study Completion Date
January 20, 2017
Evolocumab
Administered by subcutaneous injection once every 2 weeks
Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Participants received apheresis for LDL-C according the their physician's prescription and local custom.
Research Site, Heidelberg
Research Site, Berlin
Research Site, Flensburg
Research Site, Boca Raton
Research Site, Düsseldorf
Research Site, Seville
Research Site, Nantes
Research Site, Grandville
Research Site, Pisa
Research Site, Kansas City
Research Site, Bron
Research Site, Portland
Research Site, Hradec Králové
Research Site, Dresden
Research Site, Roma
Research Site, Harefield
Research Site, Penarth
Lead Sponsor
Amgen
INDUSTRY